OR WAIT null SECS
June 21, 2025
Article
New findings reveal semaglutide significantly enhances walking ability and quality of life for patients with T2D and PAD.
June 12, 2025
Video
Potentially the first successful CETP inhibitor, obicetrapib has shown positive trial results in reducing the risk of cardiovascular disease when combined with statins.
June 11, 2025
Gulati covers the promises and pitfalls of the healthcare world’s increasing focus on obesity as a disease and the variety of complications to which it gives rise.
Budoff suggests monitoring serum lipoproteins like Lp(a) and ApoB to predict cardiovascular disease risk in patients with no conventional indicators.
June 08, 2025
The pooled analysis of BROOKLYN and BROADWAY data outline obicetrapib’s impact on HbA1c reduction and a trend toward lower new-onset diabetes risk.
May 30, 2025
A recent study reveals a significant rise in cardiac deaths at home since the COVID-19 pandemic, highlighting urgent healthcare gaps.
May 28, 2025
Yale researchers unveil a groundbreaking 3D-bioprinted synthetic aorta, promising revolutionary advancements in cardiovascular disease treatment and patient care.
May 26, 2025
Discover the critical role of Lp(a) measurement in assessing cardiovascular risk and its potential impact on CVD prevention strategies.
May 22, 2025
Calprotectin emerges as a promising biomarker for predicting atherosclerotic cardiovascular disease risk, independent of traditional risk factors.
May 19, 2025
Latest analysis of the HELIOS-B trial finds vutrisiran significantly lowers mortality and cardiovascular events in patients with ATTR-CM.
